CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6 enrolled
Drug / intervention
Magnevist (gadopentetate dimeglumine)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02080312
NCT02080312N/ACompleted
CompareCT.gov

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

University of California, San Diego·interventional·Posted Mar 6, 2014·Updated Feb 12, 2016

In Brief

A clinical study evaluating Magnevist (gadopentetate dimeglumine) for Meniere's Disease. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This is a pilot study of patients with clinical symptoms of Ménière's disease using injection of diluted magnetic resonance imaging (MRI) contrast agent into the ear to evaluate inner ear structures. The goal is to reproduce imaging findings described by non-United States (US) institutions, improve on image quality with decreased scan time and evaluate the dynamics of the contrast movement into the inner ear structures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeniere's Disease
CountriesUnited States
CollaboratorsAmerican Society of Head and Neck Radiology

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 6, 2014
Enrollment StartJan 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.3 years ago

Interventions

Magnevist (gadopentetate dimeglumine)drug